Health
China Sinopharm’s Potential COVID-19 Vaccine Triggers Antibodies in Clinical Trials: Journal – The New York Times
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The shot did not cause any serious side effects, according to a paper published on Thursday in the Journal of the American Medical Association (JAMA) by scientists who are part of Sinopharm and other China-based disease control authorities and research institutes.
The results were based on data from 320 healthy adults in Phase 1 and 2 trials.
The candidate triggered robust antibody responses in inoculated people, but it remained unknown if that was sufficient to prevent COVID-19 infection, re…
-
General17 hours agoTwo people arrested after man fatally shot at McLaren Flat
-
General9 hours agoICAC investigating University of Wollongong as chancellor grilled at Inquiry
-
General16 hours agoWarner Bros Discovery board rejects rival $163bn bid from Paramount
-
General22 hours agoMan refused bail charged with depicting Adolf Hitler and Nazi symbols on boat